8-K: Encompass Health Reports Strong Q4, Issues Upbeat 2026 Guidance

Encompass Health reported robust fourth-quarter and full-year 2025 results, driven by capacity expansion and strong operational performance, alongside optimistic 2026 guidance.

Summary

• Net operating revenue for Q4 2025 was $1,544.6 million, a 9.9% increase from Q4 2024, and for the full year 2025 was $5,935.2 million, a 10.5% increase from FY 2024.
• Adjusted EBITDA for Q4 2025 reached $335.6 million, up 15.9% from Q4 2024, and for the full year 2025 was $1,267.9 million, up 14.9% from FY 2024.
• Adjusted EPS for Q4 2025 was $1.46, a 24.8% increase from Q4 2024, and for the full year 2025 was $5.45, up 23.0% from FY 2024.
• Adjusted free cash flow for Q4 2025 was $235.4 million, a 23.6% increase from Q4 2024, and for the full year 2025 was $817.9 million, up 18.5% from FY 2024.
• The company opened 8 new hospitals totaling 390 beds and added 127 beds to existing hospitals in 2025, bringing the total capacity additions to 517 beds.
• Net leverage stood at 1.9x at year-end 2025.
• Shareholder distributions included quarterly dividends of $0.17 per share in January, April, and July 2025, and $0.19 per share in October 2025.
• The company repurchased 1,465,233 shares of common stock for $158.0 million in 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, reflecting strong financial performance, strategic capacity expansion, and a confident outlook for 2026, underpinned by effective management of regulatory changes and consistent shareholder returns.

Positives

• Strong growth across all key financial metrics for Q4 and Full Year 2025, including net operating revenue (up 9.9% and 10.5% respectively), Adjusted EBITDA (up 15.9% and 14.9% respectively), Adjusted EPS (up 24.8% and 23.0% respectively), and Adjusted free cash flow (up 23.6% and 18.5% respectively).
• Significant capacity expansion with 8 new hospitals and 127 bed additions in 2025, totaling 517 new inpatient rehabilitation beds.
• Improved net leverage ratio to 1.9x at year-end 2025, indicating a stronger balance sheet.
• Increased shareholder distributions through consistent quarterly dividends and substantial share repurchases totaling $158.0 million in 2025.
• Positive 2026 guidance projecting continued growth in Net Operating Revenue ($6,365M-$6,465M), Adjusted EBITDA ($1,340M-$1,380M), and Adjusted EPS ($5.81-$6.10).
• Anticipated Medicare pricing increase of approximately 3.0% and Managed Care pricing increase of 2.0% to 3.0% for 2026.
• Demonstrated high average affirmation rate of 93% for pre-claim review in the Alabama Review Choice Demonstration (RCD).
• Proven track record of successfully managing through alternative payment models, including BPCI Original, CJR, and BPCI-A.
• Operates in a large, under-penetrated, and growing inpatient rehabilitation market, supported by favorable demographics.
• Capacity addition strategy is noted to deliver attractive financial returns and is supported by available cash flow and capital.
• Resilient business model focused on non-discretionary conditions occurring predominantly in an aging population.

Negatives

• Incurred net pre-opening and ramp-up costs of $2.9 million in Q4 2025 and $13.9 million for the full year 2025.
• Other operating expenses in Q4 2025 included an $8.3 million increase in provider tax expenses.
• General and administrative expense for Q4 2025 included approximately $4 million of Oracle Fusion post-implementation support costs.
• Expected net pre-opening and ramp-up costs of $18 million to $22 million in 2026, indicating continued investment in new facilities.
• Anticipated salaries and benefits (SWB) per FTE increase of 3.0% to 3.5% in 2026, suggesting rising labor costs.
• The Review Choice Demonstration (RCD) is expanding to new states (Texas, California) and will apply to new Pennsylvania de novos, introducing new compliance requirements and potential administrative burdens.
• The Transforming Episode Accountability Model (TEAM) bundled payment model, while having no downside risk in Year 1 (2026) for ACHs under the default track, introduces new performance-based payment structures that require adaptation.

Risks

• Estimates, projections, and forward-looking information may differ materially from actual events or results.
• Infectious disease outbreaks could decrease patient volumes and revenues, and lead to staffing and supply shortages and associated cost increases.
• Demand for services could be negatively impacted by economic downturns and consumer confidence.
• Adverse outcomes from various lawsuits, claims, and legal or regulatory proceedings.
• Inability to attract and retain key management personnel.
• Potential disruptions, breaches, or other incidents affecting information systems, including unauthorized access to sensitive information or system unavailability.
• Inability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with growth strategy.
• Increases in Medicare audit activity, potentially resulting in additional unpaid reimbursement claims and a backlog of appealed claims denials.
• Changes, delays, or suspension of reimbursement for services by governmental or private payors.
• Changes in healthcare industry regulation at federal and state levels, including the CMS inpatient rehabilitation review choice demonstration project (RCD).
• Competitive pressures in the healthcare industry.
• Inability to obtain and retain favorable arrangements with third-party payors.
• Inability to control costs, particularly labor and employee benefit costs, including group medical expenses.
• Adverse effects from coverage determinations by Medicare Administrative Contractors and lengthening delays in recovering improperly denied claims through the administrative appeals process.
• Inability to adapt to changes in the healthcare delivery system, including value-based purchasing such as the Transforming Episode Accountability Model (TEAM) and involvement in coordinated care initiatives.
• Inability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with staffing shortages, potentially worsened by infectious disease outbreaks.
• Impact on labor expenses from potential union activity, staffing shortages, and competitive compensation practices.
• General conditions in the economy and capital markets, including instability or uncertainty related to trade war, armed conflict, terrorism, governmental impasse, debt ceiling, or international sovereign debt crisis.
• Increase in the cost of, or decrease in the availability of, construction materials and necessary supplies, including as a result of tariffs and import restrictions.
• Increase in the costs of defending and insuring against alleged professional liability claims, and difficulty in predicting these estimated costs.

Future Outlook

Encompass Health projects strong growth for 2026, with net operating revenue expected to be between $6,365 million and $6,465 million, Adjusted EBITDA between $1,340 million and $1,380 million, and Adjusted EPS between $5.81 and $6.10. This guidance is supported by anticipated Medicare pricing increases of approximately 3.0% and Managed Care pricing increases of 2.0% to 3.0%, alongside plans to open 8 new hospitals (389 beds) and add approximately 175 beds to existing facilities. Labor costs are expected to increase by 3.0% to 3.5% per FTE, and net pre-opening and ramp-up costs are projected to be $18 million to $22 million. The company also anticipates a corporate tax rate of approximately 26% and a diluted share count of approximately 102 million shares.

Management Comments

• "Our Q4 performance was very strong, capping a stellar 2025."
• "Our 2025 revenue increased 10.5% and Adjusted EBITDA grew 14.9%."
• "During the year, we significantly increased our capacity, adding a total of 517 inpatient rehabilitation beds via eight new hospitals and the addition of 127 beds to existing hospitals."
• "The need for the services we provide continues to grow as the U.S. population ages. We are uniquely positioned to meet this rising demand."

Industry Context

StockSavvy.ai notes that Encompass Health's strong performance and aggressive capacity expansion strategy align with the growing demand for rehabilitation services, primarily driven by an aging U.S. population. The company is actively navigating evolving regulatory landscapes, such as the expansion of the Review Choice Demonstration (RCD) and the implementation of the Transforming Episode Accountability Model (TEAM), which are critical for Medicare fee-for-service claims and bundled payments, respectively. Its stated experience with previous alternative payment models positions it to adapt to these changes, while its focus on capacity additions addresses the under-penetrated inpatient rehabilitation market.

Comparison to Industry Standards

• StockSavvy.ai notes that while the filing highlights a large, under-penetrated market and favorable demographics, it does not provide specific comparative data against direct competitors like Kindred Healthcare or Select Medical Holdings Corporation in terms of growth rates, affirmation rates under RCD, or specific project returns.
• The company's 93% affirmation rate in Alabama RCD is strong, but without industry benchmarks for similar demonstrations, its relative performance is difficult to assess.
• The company's net leverage of 1.9x at year-end 2025 is a healthy ratio within the healthcare services sector, often considered favorable compared to a typical industry range of 2.0x to 3.5x for well-capitalized providers, but specific peer comparisons are not provided.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased dividends, and share repurchases. Future growth guidance suggests continued value creation.
• Employees: Potential for increased employment opportunities due to capacity expansion (new hospitals and bed additions). Anticipated labor cost increases (SWB per FTE increase of 3.0% to 3.5%) suggest competitive compensation.
• Patients: Increased access to high-quality, compassionate rehabilitative care through new hospitals and bed additions, addressing growing demand.
• Creditors: Improved net leverage ratio (1.9x) indicates stronger financial health and enhanced ability to service debt.
• Suppliers: Increased demand for construction materials and supplies due to ongoing development activities and capacity expansions.

Next Steps

• Open 8 new hospitals with a total of 389 beds in 2026.
• Add approximately 175 beds to existing hospitals in 2026.
• Open the first small format hospital in 2027 as part of a hub-and-spoke strategy.
• Continue to manage the Review Choice Demonstration (RCD) rollout in Texas (starting March 2026) and California (starting May 2026), and for new Pennsylvania de novos.
• Operate under the Transforming Episode Accountability Model (TEAM) bundled payment initiative from January 2026 to December 2030.
• Continue shareholder distributions through quarterly dividends and potential common stock repurchases, with approximately $332 million remaining under current authorization as of December 31, 2025.

Key Dates

Recommendation

The company delivered exceptional Q4 and full-year 2025 results, significantly outperforming previous periods across all key financial metrics. The robust 2026 guidance, coupled with aggressive capacity expansion plans (8 new hospitals and 175 bed additions), demonstrates strong growth momentum in a favorable demographic environment. The improved leverage ratio and continued shareholder returns through dividends and buybacks further enhance investor confidence. While regulatory changes like RCD and TEAM are ongoing, the company has a proven track record of adapting, and the initial RCD affirmation rates are positive. The overall outlook is highly favorable for sustained growth and profitability.

Keywords

inpatient rehabilitation, healthcare, earnings report, financial results, EBITDA, EPS, free cash flow, capacity expansion, hospital development, Medicare, Medicaid, managed care, RCD, TEAM, corporate governance, shareholder returns, debt leverage, Encompass Health